| Assessing the impact of medication use on trends in major coronary risk factors in older British men: a cohort study. | |
| | |
MedLine Citation:
|
PMID: 20386311 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
AIMS: To investigate the role of medication in 20-year trends in blood pressure (BP) and blood lipids in older British men. METHODS AND RESULTS: BP and lipids were measured in 4231 men from a representative cohort at baseline (1978-1980, aged 40-59 years) and after 20 years (1998-2000). Cohort-wide age-adjusted 20-year mean changes were as follows: systolic BP -7.6 mmHg (95% confidence interval: -9.7 to -5.4); diastolic BP +3.3 mmHg (+2.2 to +4.5); non-high-density lipoprotein (HDL)-cholesterol -0.4 mmol/l (-0.5 to -0.2); HDL-cholesterol +0.16 mmol/l (+0.13 to +0.19). Much (79%) of the systolic BP fall occurred only among 1561 men (37%) reporting the use of BP-lowering medication during the follow-up; systolic BP changed by -12.3 mmHg (-14.7 to -9.9) and -1.6 mmHg (-3.7 to +0.5) among medication users and men not using medication, respectively (P<0.001 for medication-time interaction). One-third of the non-HDL-cholesterol fall occurred only among 302 men (8%) reporting the use of lipid-regulating drugs; non-HDL-cholesterol changed by -1.8 mmol/l (-2.0 to -1.6) and -0.2 mmol/l (-0.4 to -0.1) among medication users and men not using medication, respectively (P<0.001 for interaction). The HDL-cholesterol increase was not associated with lipid-regulating drug use (P=0.15 for interaction). CONCLUSION: Decreases in BP were largely confined to medication users and overall changes in non-HDL-cholesterol were modest, suggesting the need for greater efforts to reduce BP and cholesterol among the general population. HDL-cholesterol increased among all men, likely reflecting cohort-wide improvements in associated health behaviours. |
| | |
Authors:
|
Sarah L Hardoon; Peter H Whincup; S Goya Wannamethee; Lucy T Lennon; Simon Capewell; Richard W Morris |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology Volume: 17 ISSN: 1741-8275 ISO Abbreviation: Eur J Cardiovasc Prev Rehabil Publication Date: 2010 Oct |
Date Detail:
|
Created Date: 2010-10-05 Completed Date: 2011-02-01 Revised Date: 2011-10-28 |
Medline Journal Info:
|
Nlm Unique ID: 101192000 Medline TA: Eur J Cardiovasc Prev Rehabil Country: England |
Other Details:
|
Languages: eng Pagination: 502-8 Citation Subset: IM |
Affiliation:
|
Department of Primary Care and Population Health, Division of Population Health, UCL, London, UK. s.hardoon@ucl.ac.uk |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Age Factors Antihypertensive Agents / therapeutic use* Biological Markers / blood Blood Pressure / drug effects Cholesterol / blood Cholesterol, HDL / blood Cohort Studies Coronary Artery Disease / epidemiology, etiology, prevention & control* Drug Utilization Dyslipidemias / blood, complications, drug therapy*, epidemiology Great Britain / epidemiology Health Behavior Humans Hypertension / complications, drug therapy*, epidemiology, physiopathology Hypolipidemic Agents / therapeutic use* Linear Models Male Middle Aged Risk Assessment Risk Factors Time Factors Treatment Outcome |
| Grant Support | |
ID/Acronym/Agency:
|
G0701739//Medical Research Council; G0701739(85531)//Medical Research Council; RG/04/003//British Heart Foundation |
| Chemical | |
Reg. No./Substance:
|
0/Antihypertensive Agents; 0/Biological Markers; 0/Cholesterol, HDL; 0/Hypolipidemic Agents; 57-88-5/Cholesterol |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Ligands of the receptor for advanced glycation end products, including high-mobility group box 1, li...
Next Document: Meta-analysis on the relationship between nonsteroidal anti-inflammatory drug use and gastric cancer...